4591 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes the Ribomic Aptamer Therapeutics (RiboART) system to discover new drugs that are applicable to target proteins. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
4591 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company